RLAY Relay Therapeutics, Inc.
Legal ·
Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss.
Relay Therapeutics amended its stock sales agreement on August 6, 2026 to add $212,978,049 of at-the-market sales, raising the program to $462,978,049. The prospectus puts immediate dilution at $14.22 a share for investors who buy in the offering.
Common stock authorized rises from 300,000,000 shares. Relay filed the amendment in Delaware on June 9, 2026.
Relay paid a lease modification payment of approximately $2.5 million and a relocation payment of approximately $3.5 million. It says the changes cut rent expense by approximately $16 million.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $15.4 million | $10.0 million |
| Net income (loss) | -$276.5 million | -$337.7 million |
| Cash from operations | -$235.5 million | -$249.1 million |
| Cash and equivalents | $84.0 million | $124.3 million |
Our latest story on this, dated Aug 6, 2026: "Relay Therapeutics adds $212,978,049 to at-the-market stock program". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 6, 2026: "Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay". The story links the filing or release it is based on. Read the story.
Relay Therapeutics, Inc. trades under the ticker RLAY on NASDAQ.
Relay Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Relay Therapeutics, Inc. is 1812364. Its filings are on SEC EDGAR.
219,141,631 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Relay Therapeutics, Inc. under United States.
Our directory classifies Relay Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Relay Therapeutics, Inc. is US75943R1023.
aibio.space lists Relay Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$15.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Relay Therapeutics, Inc. reported a net loss of $276.5 million for the fiscal year ended Dec 31, 2025, and used $235.5 million of cash in operations, per its annual report to the SEC.
$121.2 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Relay Therapeutics, dated Aug 6, 2026: "Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay". Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss. Source.
Reported a financing. SEC Form 8-K (Items 1.01,2.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio